# Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)

> **NCT03945318** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 103 (actual)

## Conditions studied

- IgA Nephropathy

## Interventions

- **DRUG:** BION-1301 Single Dose
- **DRUG:** Placebo Single Dose
- **DRUG:** BION-1301 Multiple Doses
- **DRUG:** Placebo Multiple Doses
- **DRUG:** BION-1301 Single Dose

## Key facts

- **NCT ID:** NCT03945318
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-04-08
- **Primary completion:** 2026-04-30
- **Final completion:** 2026-04-30
- **Target enrollment:** 103 (ACTUAL)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03945318

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03945318, "Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03945318. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*